Company intelligence / Profile preview

KdT Ventures

Austin, Texas, United Stateskdtvc.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

KdT Ventures does not develop drugs directly but invests in early-stage companies across biotechnology, healthcare, computational chemistry, and related fields. Its portfolio includes companies at various clinical stages from pre-clinical to early clinical development.

Industry: Investors

Partnerships

NGM Biopharmaceuticals — worldwide license agreement for NGM313 FGFR1c/β-Klotho agonist drug candidate in December 2024

Beyond the preview

Go deeper on KdT Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KdT Ventures.